Since the introduction of 177Lu-labeled radioligands targeting PSMA, multiple studies have included descriptive analyses of hematologic adverse events, overall reporting moderate rates of grade ≥ 3 toxicities in the range of 8–24% for anemia, 0–8% for leukopenia and 1–11% for thrombocytopenia [14,15,38,46]. The gene discussed is FOLH1; the disease is anemia.